Welcome to our dedicated page for China Jo-Jo Drugstores news (Ticker: CJJD), a resource for investors and traders seeking the latest updates and insights on China Jo-Jo Drugstores stock.
China Jo-Jo Drugstores, Inc. (CJJD) is described in its public communications as an online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. The CJJD news page on Stock Titan aggregates company-specific announcements, market disclosures and other coverage related to this pharmacies and drug stores issuer.
Recent news releases highlight several themes in CJJD’s developments. The company has reported fiscal year 2024 financial results, with revenue reported across retail drugstores, online pharmacy and wholesale segments. It has discussed changes in segment performance, gross margin, operating expenses and net loss, as well as its use of modern wholesale platforms to reach buyers in the pharmaceutical distribution market.
CJJD’s news flow also includes capital markets activity, such as multiple registered direct offerings of ordinary shares under an effective shelf registration statement on Form F-3. These announcements describe the size of each offering, the purchase price per share and the company’s stated intention to use net proceeds for general corporate purposes and working capital.
Another recurring topic is CJJD’s Nasdaq listing status. The company has issued press releases about receiving extensions from Nasdaq to meet the minimum bid price requirement, implementing a 1-for-20 reverse stock split of its ordinary shares and later regaining compliance with Nasdaq’s minimum bid price rule.
More recently, CJJD announced definitive agreements for a strategic restructuring to transition toward an asset-light, wholesale-focused model. This includes a planned acquisition of Allright (Hangzhou) Internet Technology Co. Ltd., which is engaged in pharmaceutical wholesale, and a planned sale of CJJD’s drug retail business to certain existing shareholders and their affiliates, subject to shareholder approval and other conditions.
Investors and observers using the CJJD news page can review these types of updates in one place, including earnings announcements, financing transactions, listing compliance notices and strategic restructuring plans, to better understand how the company describes its operations and corporate actions over time.
China Jo-Jo Drugstores (NASDAQ: CJJD) addressed shareholders in a letter highlighting challenges faced during the 2020 COVID-19 pandemic. The national pharmaceutical retail market in China saw a decline of 1.7%. Despite this, the company achieved remarkable growth, with Daguan store sales soaring 323% year-over-year. Online revenue surged by 26.1% during the "618" festival and 64.5% during "Double 11". Looking forward to 2021, the company aims to enhance its digital transformation and service quality while continuing partnerships to improve healthcare delivery.
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) recently hosted its inaugural suppliers conference in Hangzhou, China, attended by around 200 supplier representatives. The event resulted in strategic cooperation framework agreements with 11 notable companies, including Pfizer and AstraZeneca. CEO Lei Liu emphasized the importance of ethical conduct and adaptability amid the evolving pharmaceutical landscape in China. Jo-Jo Drugstores aims to enhance its product offerings and maintain strong relationships with suppliers as it faces challenges in the post-epidemic era.
On December 23, 2020, China Jo-Jo Drugstores (NASDAQ: CJJD) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) concerning minimum bid price requirements. This follows a notification from Nasdaq on October 16, 2020, indicating that the company's stock had fallen below the minimum bid price of $1.00 for 30 consecutive business days. Nasdaq confirmed that from November 18 to December 14, 2020, the closing bid price was at least $1.00, allowing the company to meet the listing requirement.
China Jo-Jo Drugstores (NASDAQ: CJJD) reported its financial results for the second fiscal quarter ending September 30, 2020. Revenue increased by 8.8% to $30.84 million, with gross profit rising 4.8% to $7.01 million. Online pharmacy sales surged 127.4% year-over-year. However, net loss rose to $1.53 million, maintaining a loss per share of $0.04. The company improved its cash position to $21.65 million from $16.18 million in March 2020. The overall gross margin decreased slightly to 22.7%.
Summary not available.
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) reported strong results for the first fiscal quarter ended June 30, 2020, with revenue growing by 22.8% to $31.05 million and gross profit increasing 31.7% to $7.98 million. Retail drugstore sales rose 12.4%, while online pharmacy revenue surged 101.1%. Despite these gains, the company reported a net loss of $0.39 million, a significant improvement from $2.38 million the previous year. The transformation strategy aims to enhance service quality and brand awareness amidst market volatility.
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) reported financial results for the fiscal year ending March 31, 2020, with revenues of $117.33 million, a 9.1% increase from $107.55 million in 2019. Retail drugstore revenue rose 2.4%, online pharmacy grew by 54.1%, and wholesale increased 12.4%. However, the company faced a net loss of $6.46 million, compared to a $1.32 million loss the previous year. Gross margin also decreased by 1.5 percentage points to 21.8%. Despite these challenges, positive growth in online and wholesale sales provided some resilience amid the pandemic.